DUBLIN--(BUSINESS WIRE)--May 14, 2018--The "Drug Overview: Advair" report has been added to ResearchAndMarkets.com's offering.

Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol). The drug has anti-inflammatory and bronchodilatory effects on patients with asthma. It is administered twice daily through a dry powder inhaler device called Advair Diskus, or a pressurized metered-dose inhaler device known as Advair hydrofluoroalkane (HFA).

Key Topics Covered:

Product Profiles

Advair: Asthma

Advair: Chronic obstructive pulmonary disease (COPD)

List of Figures

Figure 1: Advair for asthma - SWOT analysis

Figure 2: Drug assessment summary of Advair in asthma

Figure 3: Drug assessment summary of Advair in asthma

Figure 4: Advair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

Figure 5: Advair for COPD - SWOT analysis

Figure 6: Drug assessment summary of Advair for COPD

Figure 7: Drug assessment summary of Advair for COPD

List of Tables

Table 1: Advair drug profile

Table 2: Advair Diskus pivotal trial data in asthma

Table 3: Advair HFA pivotal trial data in asthma

Table 4: Advair late-phase trial data in asthma

Table 5: Advair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 6: Advair drug profile

Table 7: Overview of pivotal trial data for Advair Diskus in COPD

For more information about this report visit https://www.researchandmarkets.com/research/z8gsws/advair?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180514006225/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/14/2018 02:47 PM/DISC: 05/14/2018 02:47 PM

http://www.businesswire.com/news/home/20180514006225/en